issue at .42, page-2

They are just running a tight ship by making a small issue which just covers costs of expansion. At the point of selling to the world is a great time to buy into a company like this. I'm sure Cochlear didn't attract much attention in the early days, not until the money flowed in; they also didn't expand the share numbers. I suspect that the technology CCE are using on skin can be expanded to other cell culture tissue engineering in the future. Skin repair is also reasonably recession proof as burns are not put off as elective surgery. The placement to an institution gives a guide as the direction the company is heading. Expect some further announcements after the share offer closes on 14/9.